More than 50% of patients hospitalized for heart failure (HF) are reported to have HF with persevered ejection fraction (HFpEF). In addition, due to its complex pathophysiology, disease heterogeneity, and cardiac- or extracardiac-related comorbidities, limited therapies are available to treat HFpEF. Here's a Journal Watch that discusses the “ Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: Insights from the PROMIS-HFpEF study ” published in the European Journal of Heart Failure , October 2022.
1 What was the need for the study? Epicardial adipose tissue (EAT) is associated with obesity and is increased in HFpEF patients compared to individuals without HFpEF. 2 EAT may cause microcirculatory dysfunction that leads to cardiac remodeling and myocardial…
